This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Tuberculosis결핵 (폐결핵)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: A15 (respiratory tuberculosis, bacteriologically and histologically confirmed) | Special Copayment Reduction: V000 (tuberculosis special copayment reduction: applies to tuberculosis patients reported under the Tuberculosis Prevention Act who are undergoing treatment; applicable disease codes include A15–A19 and anti-tuberculosis drug resistance U84.3)
B. SynonymsTuberculosis, pulmonary tuberculosis, tuberculosis disease, TB (Tuberculosis), Koch's disease, Mycobacterium tuberculosis infection, Active tuberculosis, Extrapulmonary tuberculosis, Miliary tuberculosis, multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB), rifampin-resistant tuberculosis (RR-TB), consumption (former name)
C. Adult onsetVery high likelihood of first manifestation in adulthood. The most common clinical presentation of tuberculosis is infection in childhood followed by years to decades of latency, with reactivation and first manifestation as active disease in adulthood when immunity declines, particularly triggered by old age, diabetes, immunosuppressive therapy, HIV infection, etc.; more than half of new patients in Korea are first diagnosed at age 65 or older.
1. HistoryA history of conquest of humanity's oldest chronic infectious disease, from Koch's identification of the causative organism in 1882, through the development of BCG and streptomycin, to multidrug therapy and national control programs.
2. CausesA chronic granulomatous infection caused by the Mycobacterium tuberculosis complex; airborne transmission via droplet nuclei is the only major route of transmission.
3. GeneticsResistance genes of the pathogen such as rpoB, katG and embB, and host genes of the SLC11A1, HLA and IFN-γ axis determine susceptibility to infection and disease course.
4. General epidemiologyIn 2024 there were 10.7 million new cases and 1.23 million deaths worldwide; in Korea, cases declined for the 13th consecutive year, with 17,944 new cases (35.9/100,000) recorded.
5. PathophysiologyInhaled tubercle bacilli are phagocytosed by alveolar macrophages and form granulomas; depending on the state of cell-mediated immunity, the outcome is either latent infection or active disease.
6. SymptomsCharacterized by cough lasting 2 weeks or longer, hemoptysis, low-grade fever, night sweats and weight loss, accompanied by various local symptoms depending on the organ involved.
7. SignsPhysical findings appear according to the site involved, such as crackles and decreased breath sounds on auscultation, signs of pleural effusion, lymphadenopathy, spinal kyphotic deformity, and signs of meningeal irritation.
8. ScreeningLatent tuberculosis is screened with the tuberculin skin test and IGRA, and in high-risk groups chest X-ray and contact investigation are performed in parallel.
9. DiagnosisIn addition to sputum smear and culture, molecular diagnostic tests such as Xpert MTB/RIF rapidly and simultaneously confirm the organism and determine rifampin resistance.
10. TreatmentFor drug-susceptible tuberculosis, the standard 4-drug regimen (6 months) is the mainstay; a 4-month rifapentine short-course regimen and the 6–9-month BPaLM regimen for multidrug-resistant tuberculosis have been newly introduced.
11. PrognosisThe cure rate of drug-susceptible tuberculosis is over 95%, but the treatment success rate for multidrug-resistant tuberculosis is low at 60% or less, and pulmonary function sequelae may remain even after cure.
12. PreventionBCG vaccination, contact investigation, treatment of latent tuberculosis, and airborne precautions in healthcare facilities are the core pillars of tuberculosis prevention and transmission control.
13. ReferencesGlobal Tuberculosis Report 2024 … and 9 other papers

1. History

Tuberculosis is one of the infectious diseases that has coexisted with humanity the longest; archaeological evidence shows tuberculous lesions in Neolithic skeletal remains from about 9,000 years ago, and records of wasting disease remain in texts from ancient India (about 3,300 years ago) and China (about 2,300 years ago). Until the modern era, tuberculosis was mistakenly regarded as a hereditary disease or a constitutional wasting disease, and in 19th-century Europe it was so prevalent, affecting a large proportion of the population, that it was called the "White Plague."

The turning point in tuberculosis research came on March 24, 1882, when Robert Koch, at the Physiological Society of Berlin, isolated and identified the acid-fast bacillus Mycobacterium tuberculosis and proved through Koch's postulates that this organism was the cause of tuberculosis. This discovery established tuberculosis as an infectious disease rather than a hereditary one, and Koch received the Nobel Prize in Physiology or Medicine in 1905. From the 1890s to the mid-20th century, sanatorium-based fresh air, rest and nutrition therapy became the main treatment, and sanatoria were so widely operated that in the United States alone, as of 1953, about 136,000 people were treated in 839 sanatoria.

In diagnosis, Florence Seibert standardized purified protein derivative (PPD) in the 1930s, laying the foundation for the tuberculin skin test; in prevention, Albert Calmette and Camille Guérin developed the BCG (Bacille Calmette-Guérin) vaccine in 1921 using an attenuated strain of Mycobacterium bovis, contributing to the prevention of severe tuberculosis in children (miliary tuberculosis, tuberculous meningitis).

The fundamental shift in treatment came in 1943 when Selman Waksman, Elizabeth Bugie and Albert Schatz discovered streptomycin, the first anti-tuberculosis chemotherapeutic agent, which transformed tuberculosis from an incurable disease into a treatable one (Waksman received the Nobel Prize in 1952). Subsequently, isoniazid (1952), rifampin (1960s) and others were introduced in sequence, establishing the current multidrug combination therapy system. The World Health Organization (WHO) adopted the DOTS (Directly Observed Treatment, Short-course) strategy in the 1990s and, in 2014, the End TB Strategy, which aims to drastically reduce tuberculosis incidence and mortality by 2035.

In Korea, a nationwide management system was built starting with the National Tuberculosis Control Program in 1962, and diagnostic and treatment standards have since been continually updated through the KDCA National Tuberculosis Management Guidelines and the tuberculosis treatment guidelines jointly issued by the Korean Academy of Tuberculosis and Respiratory Diseases and the KDCA (5th edition revised in 2024).


2. Causes

The causative pathogen of tuberculosis is the Mycobacterium tuberculosis complex (MTBC), which includes M. tuberculosis, M. bovis, M. africanum, M. canettii, M. microti, M. caprae, and others. Clinically, most cases are caused by M. tuberculosis, and M. bovis infection acquired through consumption of unpasteurized dairy products presents mainly as gastrointestinal or cervical lymph node tuberculosis. Tubercle bacilli are acid-fast bacilli that stain positive on acid-fast staining because of the very high lipid content of their cell wall, including mycolic acid; they are obligate aerobes with a generation time of about 15–20 hours, making them very slow-growing pathogens that take 3–8 weeks to form visible colonies on solid media. Humans are known to be the only major natural host.

Transmission is almost exclusively airborne: susceptible individuals become infected by inhaling droplet nuclei (1–5 μm in diameter) expelled by patients with active pulmonary or laryngeal tuberculosis when coughing, sneezing, talking or vocalizing. Infectiousness is closely related to sputum smear positivity, the presence of cavitary lesions, cough frequency, and duration of exposure in enclosed or poorly ventilated spaces; contact investigation is usually conducted assuming a potential infectious period of at least 3 months before onset. In contrast, persons with latent tuberculosis infection or with extrapulmonary tuberculosis alone are generally not infectious to others.

Whether infection actually progresses to active disease depends largely on the host's immune status. Major risk factors include HIV infection (risk of developing active tuberculosis increased about 12–19-fold compared with uninfected persons), diabetes mellitus, chronic renal failure and dialysis, silicosis, malnutrition, smoking, excessive alcohol consumption, immunosuppressive therapy including biologics such as tumor necrosis factor-alpha (TNF-α) inhibitors and steroids, solid organ and hematopoietic stem cell transplantation, low body weight, and immunosenescence in old age. These factors impair the bactericidal capacity of macrophages and the Th1-type cell-mediated immune response (mediated by IFN-γ and TNF-α), promoting failure to contain the bacilli and granuloma breakdown, thereby triggering the transition from latent infection to active disease.


3. Genetics

Tuberculosis is not a single-gene Mendelian genetic disorder but a multifactorial infectious disease in which both the pathogen genotype and the host genetic background influence susceptibility, severity and drug response.

On the pathogen side, M. tuberculosis lineages are phylogenetically classified into Lineages 1–7, and among these the Beijing genotype, common in East Asia, has been reported to show relatively high transmissibility and a tendency to acquire drug resistance. Clinically, the most important are acquired mutations that cause drug resistance: mutations in the rifampin resistance-determining region (RRDR) of the rpoB gene account for about 95% or more of rifampin resistance; katG (especially S315T) and inhA promoter mutations are associated with isoniazid resistance; and embB is associated with resistance to ethambutol, pncA to pyrazinamide, gyrA/gyrB to fluoroquinolones, and rrs to injectable aminoglycosides. These mutations are used as targets for molecular diagnostics such as Xpert MTB/RIF, line probe assay and whole-genome sequencing, allowing resistance to be predicted within hours to days without phenotypic testing.

On the host genetics side, twin studies have reported a significantly higher concordance rate of tuberculosis in monozygotic than in dizygotic twins, supporting the existence of genetic susceptibility. A representative candidate gene is SLC11A1 (formerly NRAMP1), which encodes a metal ion transporter in macrophages; in a meta-analysis, a specific 3´UTR polymorphism showed a significant association with tuberculosis susceptibility (odds ratio about 1.35, 95% confidence interval 1.17–1.54). In addition, polymorphisms or rare pathogenic variants in HLA class II (DR, DQ) alleles involved in antigen presentation, Toll-like receptor (TLR2, TLR4) polymorphisms, the vitamin D receptor (VDR) gene, and genes of the IFN-γ/IL-12 signaling axis (IFNGR1, IL12RB1, STAT1, etc.) affect susceptibility. In particular, single-gene variants causing complete deficiency of the IFN-γ/IL-12 axis give rise to a rare syndrome called "Mendelian susceptibility to mycobacterial disease (MSMD)," which can cause disseminated and severe tuberculosis in childhood.


4. General epidemiology

According to the World Health Organization (WHO) Global Tuberculosis Report 2024, about 10.7 million people (5.8 million men, 3.7 million women, 1.2 million children) newly fell ill with tuberculosis worldwide in 2024, and deaths from tuberculosis reached about 1.23 million, including 150,000 with HIV coinfection, so tuberculosis remains the leading cause of death from a single infectious agent. About one quarter of the world's population is estimated to have latent tuberculosis infection, of whom only 5–10% progress to active disease during their lifetime. Among patients with multidrug-resistant/rifampin-resistant tuberculosis (MDR/RR-TB), the proportion who actually accessed treatment was only about 2 in 5 as of 2024, so the diagnosis and treatment gap remains large. Since 2000, tuberculosis control programs worldwide are estimated to have saved about 83 million lives.

Based on the KDCA 2024 Tuberculosis Patient Notification Status, the number of new patients in Korea in 2024 was 17,944, a decrease of 8.2% from the previous year, marking the 13th consecutive annual decline since notification statistics began. The new case rate (incidence) per 100,000 population was 35.9, about 64.5% lower than the peak of 100.8 in 2011. However, there is marked variation by age: the elderly aged 65 and older accounted for 58.7% (10,534) of all new patients, and the incidence in this age group was 105.8 per 100,000 population, about 6 times that of those under 65 (18.0), so population aging has emerged as a key challenge for tuberculosis control in Korea. The proportion of foreign tuberculosis patients was 6.0% (1,077), increasing every year, and multidrug-resistant and rifampin-resistant tuberculosis cases numbered 461, a 16.3% decrease from the previous year (551). Despite this declining trend, Korea still belongs to the group of OECD member countries with the highest tuberculosis incidence and mortality.

By comparison, according to US CDC 2023 statistics, there were 9,615 new cases (2.9 per 100,000 population), a 16% increase from the previous year, of which 76% occurred in foreign-born persons, and about 85% of active tuberculosis was analyzed as arising from reactivation of past latent infection, suggesting that tuberculosis control in low-burden countries is increasingly shifting toward a focus on latent tuberculosis management.


5. Pathophysiology

The development of tuberculosis begins with the inhalation of droplet nuclei. Droplet nuclei 1–5 μm in diameter pass the upper airway defense mechanisms and reach the alveoli, where they are phagocytosed by alveolar macrophages. Tubercle bacilli secrete virulence factors such as ESAT-6 and CFP-10 via the ESX-1 secretion system, inhibiting phagosome–lysosome fusion, and adopt an intracellular parasitic strategy of surviving and multiplying within macrophages. Bacilli that multiply locally in the early stage of infection are carried by dendritic cells to regional lymph nodes, where antigen presentation takes place; this activates antigen-specific CD4+ Th1 cells, inducing a cell-mediated immune response that enhances the bactericidal capacity of macrophages via IFN-γ and TNF-α. This process usually takes 3–8 weeks after infection, and around this time the tuberculin skin test and IGRA convert to positive.

As a result of the cell-mediated immune response, a granuloma forms at the site of infection, composed of epithelioid histiocytes, Langhans giant cells and a lymphocyte layer, with caseous necrosis at its center. In about 90% of immunocompetent adults, this granuloma effectively contains bacterial growth, leading to a clinically asymptomatic state of latent tuberculosis infection; when the primary focus is seen together with ipsilateral hilar lymphadenopathy, this is called the Ghon complex, and the calcified form after healing is called the Ranke complex.

In contrast, in the approximately 5–10% whose immunity is compromised or who fail to control the initial infection, the disease progresses to progressive primary tuberculosis or reactivation (secondary) tuberculosis. Reactivation tuberculosis predominantly occurs in the apical and posterior segments of the upper lobes, where high oxygen tension favors the growth of the aerobic tubercle bacillus; when the caseous necrotic material at the center of a granuloma liquefies and communicates with a bronchus, a cavity forms, within which bacilli multiply massively, sharply increasing bacillary shedding in sputum and infectiousness. When bacilli that escape local containment disseminate hematogenously or lymphatically, miliary TB and extrapulmonary tuberculosis involving organs throughout the body may develop, including the pleura, lymph nodes, bones and spine (Pott's disease), central nervous system (tuberculous meningitis), genitourinary tract, peritoneum and intestine, and pericardium. In HIV coinfection, granuloma formation itself is incomplete, increasing the frequency of atypical imaging findings and disseminated disease, and after initiation of antiretroviral therapy the clinical picture may temporarily worsen due to immune reconstitution inflammatory syndrome (IRIS) accompanying immune recovery.


6. Symptoms

Latent tuberculosis infection is by definition completely asymptomatic and is not accompanied by radiological or microbiological abnormalities. The typical symptoms of active pulmonary tuberculosis are characterized by insidious onset and a chronic course progressing over weeks to months, with cough lasting 2 weeks or longer being the most common initial symptom. As the disease progresses, sputum production, hemoptysis (common with cavitary lesions), and pleuritic chest pain with pleural involvement may occur. Characteristic systemic symptoms include low-grade fever, especially night sweats, weight loss, anorexia and generalized fatigue, and a combination of these findings strongly suggests tuberculosis. In children, the elderly, people living with HIV and others, symptoms are often atypical or mild, frequently delaying diagnosis.

The symptom pattern of extrapulmonary tuberculosis varies greatly depending on the organ involved. Cervical and supraclavicular lymph node tuberculosis (formerly called scrofula) presents as a painless, slowly enlarging neck mass, and in some cases forms drainage and fistulas. Pleural tuberculosis presents with chest pain and dyspnea due to pleural effusion. Tuberculous meningitis is characterized by subacutely progressive headache, fever, altered consciousness and meningeal irritation symptoms, and has a poor prognosis when diagnosis and treatment are delayed. Osteoarticular tuberculosis, especially spinal tuberculosis (Pott's disease), presents with local low back or back pain progressing slowly over months and may be accompanied by neurological deficits. Genitourinary tuberculosis can cause sterile pyuria, symptoms resembling recurrent urinary tract infection, flank pain, and, in women, infertility. Abdominal tuberculosis presents with ascites, abdominal pain and symptoms resembling bowel obstruction, requiring differentiation from inflammatory bowel disease. Pericardial tuberculosis presents with chest pain, dyspnea and, in severe cases, symptoms of cardiac tamponade. Miliary tuberculosis shows a disseminated clinical picture characterized by fever of unknown origin, generalized weakness and hepatosplenomegaly without distinct local symptoms.

In patients with diabetes, tuberculosis symptoms often appear intermingled with worsening glycemic control, so tuberculosis should be considered in the differential diagnosis when unexplained failure of glycemic control or weight loss persists. In elderly and immunosuppressed patients, fever is often minimal or absent and cough and sputum may not be prominent, so anorexia, slowly progressive weight loss and general functional decline may be the only clinical indicators. Even when a nodular lesion (tuberculoma) is incidentally found on chest imaging, there may be no clinical symptoms at all, making the differentiation of asymptomatic lesions from other nodular diseases such as lung cancer an important clinical task.


7. Signs

It is clinically important that physical examination findings in tuberculosis may be nonspecific or even normal depending on the stage of disease and the site involved, so tuberculosis is difficult to exclude on examination findings alone. In pulmonary tuberculosis, crackles (especially late-inspiratory crackles) may be heard over the upper lobes on auscultation; dullness to percussion and decreased breath sounds may be observed over areas with parenchymal consolidation or pleural effusion, and amphoric breath sounds over cavitary lesions. In chronically advanced extensive disease, cachexia from systemic wasting and chest wall deformity may appear.

In lymph node tuberculosis, cervical and supraclavicular lymph nodes are palpated as firm and matted together; they are painless initially but become tender with progression, and may drain, leading to cutaneous fistulas and scrofuloderma. In pleural tuberculosis with pleural effusion, the typical triad of decreased tactile fremitus, dullness to percussion and decreased breath sounds on the affected side is observed. In spinal tuberculosis, gibbus deformity together with local spinal tenderness is characteristic, and spinal cord compression may be accompanied by focal neurological deficits such as lower limb weakness and paresthesia. In tuberculous meningitis, nuchal rigidity, Kernig and Brudzinski signs, cranial nerve palsies including sixth cranial nerve palsy, and papilledema on funduscopic examination may be observed. In miliary tuberculosis, choroidal tubercles on funduscopic examination appear as a characteristic finding along with hepatosplenomegaly.

As an immune-mediated skin reaction, erythema nodosum may appear in association with active tuberculosis, especially primary tuberculosis in adolescents and young adults; this is an expression of hypersensitivity rather than direct skin infection. Rarely, findings of cutaneous tuberculosis with direct skin involvement, such as lupus vulgaris and tuberculids, are observed. Because these local physical findings are nonspecific on their own, they must be assessed comprehensively together with history, imaging and microbiological tests.

Regarding vital signs, a chronic low-grade fever (37.5–38.5°C) is often prominent in the afternoon and evening, and in acute exacerbation or disseminated disease a high fever of 39°C or higher with tachycardia may be present. It is clinically useful to measure and track body weight quantitatively at every examination; unintentional weight loss of 5% or more over weeks to months is used as an objective sign strongly suggestive of active tuberculosis. In elderly patients these typical vital sign abnormalities are often not prominent, so even subtle weight loss or functional decline warrants active reassessment.


8. Screening

Tuberculosis screening is broadly divided into tests to detect latent tuberculosis infection in asymptomatic high-risk groups, and active surveillance for early detection of active tuberculosis in symptomatic persons and high-risk groups.

The main tests for latent tuberculosis infection screening are the Tuberculin skin test (Mantoux/PPD) and the Interferon-gamma release assay (IGRA; QuantiFERON-TB Gold Plus, T-SPOT.TB, etc.). TST has a sensitivity of about 34–80%, limited in states of low bacillary burden; false positives may occur due to prior BCG vaccination or exposure to nontuberculous mycobacteria, and false negatives due to recent infection, immunosuppression, old age or improper administration. Interpretation criteria (induration 5 mm/10 mm/15 mm) are applied differentially according to the subject's level of risk. IGRA has no cross-reaction with BCG vaccination and therefore high specificity, is preferred in countries with universal BCG vaccination such as Korea, and may be more sensitive than TST in some people with HIV coinfection, but the frequency of indeterminate results may increase in children under 5 years of age and in severely immunocompromised persons with CD4+ <200/μL.

Priority target groups for screening include people living with HIV, close contacts of patients with active tuberculosis, persons scheduled to receive biologics such as TNF-α inhibitors, patients with silicosis, candidates for and recipients of solid organ and hematopoietic stem cell transplantation, dialysis patients, immigrants and long-term residents from high tuberculosis burden countries, healthcare workers, and residents of congregate settings such as correctional facilities and homeless shelters. In Korea, under the Tuberculosis Prevention Act, latent tuberculosis infection screening is institutionalized for workers in specific facilities such as healthcare institutions, schools and social welfare facilities.

Chest X-ray is widely used for active surveillance and screening for active tuberculosis; in particular, for high-risk groups (residents of institutions, close contacts, people living with HIV), the WHO recommends systematic screening combining chest X-ray and rapid molecular diagnostic testing regardless of symptoms, because simple symptom screening alone has low sensitivity and may miss a considerable number of active tuberculosis cases that are asymptomatic or have atypical symptoms.


9. Diagnosis

When active tuberculosis is clinically suspected, chest X-ray is performed first. Primary tuberculosis often shows middle and lower lobe infiltrates, intrathoracic lymphadenopathy (especially in children and people living with HIV) and pleural effusion, whereas reactivation (secondary) tuberculosis is characterized by patchy consolidation and cavitary lesions (20–45% of adults) in the apical and posterior segments of the upper lobes. In patients with advanced immunosuppression, in whom atypical findings are common, chest CT helps identify subtle lesions.

For microbiological confirmation, acid-fast bacilli smear (sensitivity 34–80%) and mycobacterial culture (sensitivity 80–93%, specificity about 93%; the reference standard for diagnosis, but taking about 2 weeks in liquid media and up to 8 weeks in solid media) are performed on sputum (induced sputum or bronchial washing if spontaneous sputum is difficult to obtain). The key recent change in the diagnostic pathway is the early introduction of molecular diagnostic testing: both the WHO and the Korean tuberculosis treatment guidelines (5th edition, 2024) recommend performing automated cartridge-based nucleic acid amplification tests such as Xpert MTB/RIF/Ultra first, from the moment tuberculosis is suspected. According to a Cochrane systematic review (Horne et al., 2019, including 95 studies), Xpert MTB/RIF has a sensitivity of about 85% and specificity of about 98% for tuberculosis detection, and a sensitivity of about 96% and specificity of about 98–99% for detection of rifampin resistance, allowing confirmation of the organism and early screening for multidrug-resistant tuberculosis simultaneously within about 2 hours. This represents a shift from the past approach of performing rapid resistance testing only when multidrug resistance was suspected, to a strategy of performing molecular testing from the initial stage of diagnosis to detect drug-resistant tuberculosis early. Subsequently, the resistance profile for other drugs is further confirmed by line probe assay, phenotypic drug susceptibility testing or whole-genome sequencing.

For the diagnosis of extrapulmonary tuberculosis, acid-fast bacilli smear, culture and nucleic acid amplification tests on involved tissues and fluids (lymph node, pleural fluid, cerebrospinal fluid, ascites, joint fluid, tissue biopsy specimens) are used, along with adenosine deaminase (ADA) measurement as an adjunct. Pleural and peritoneal fluid ADA has a reported sensitivity and specificity of around 90%, and cerebrospinal fluid ADA has a reported sensitivity of about 85% and specificity of about 90% for the diagnosis of tuberculous meningitis. Granulomas with caseous necrosis on tissue biopsy strongly suggest tuberculosis, but combined interpretation with acid-fast staining, culture and molecular testing is needed to differentiate from nontuberculous mycobacterial disease, sarcoidosis, etc. In advanced HIV infection (CD4+ <200/μL) with symptoms suggestive of tuberculosis, the urine lipoarabinomannan (LAM) test is recommended by the WHO as an adjunct.


10. Treatment

Standard treatment of drug-susceptible pulmonary tuberculosis is a 6-month regimen consisting of a 2-month intensive phase (4-drug combination of isoniazid, rifampin, pyrazinamide and ethambutol) and a 4-month continuation phase (isoniazid, rifampin). If culture remains positive at 2 months or there are extensive cavitary lesions, or with concomitant malnutrition or immunosuppression, the continuation phase can be extended by 3 months, increasing the total treatment duration to up to 9 months. Recently, a rifapentine-based regimen that shortens treatment to 4 months (an 8-week intensive phase of isoniazid + rifapentine + pyrazinamide + moxifloxacin, followed by a 9-week continuation phase of rifapentine + isoniazid + moxifloxacin) has been introduced for patients aged 12 years or older who are not pregnant and have mild disease without cavitary lesions. In addition, the TRUNCATE-TB trial (Paton et al., N Engl J Med 2023) showed that an 8-week intensified combination therapy strategy, with retreatment on relapse, was noninferior to the standard 24-week regimen in clinical outcomes at week 96, providing evidence that the treatment duration for drug-susceptible tuberculosis may be further shortened in the future. Treatment is in principle given as directly observed therapy (DOT) to improve adherence and cure rates.

Treatment of latent tuberculosis infection is given to prevent progression to active tuberculosis; the regimen preferentially recommended by the US CDC is the 3HP regimen, a 3-month course of once-weekly rifapentine plus isoniazid, which is shorter than the conventional 6–9-month isoniazid monotherapy and has a lower incidence of hepatotoxicity. In addition, 4 months of rifampin monotherapy (4R) and 3–4 months of rifampin + isoniazid combination therapy are used as alternatives, and the Korean tuberculosis treatment guidelines (5th edition) have also been revised to make rifampin-containing short-course regimens the preferred alternatives for standard latent tuberculosis treatment.

Treatment of multidrug-resistant tuberculosis (MDR/RR-TB) and extensively drug-resistant tuberculosis is the area that has undergone the greatest changes in recent years. Previously, an 18–20-month long-term multidrug regimen including injectables was standard, but all-oral short-course regimens (BPaLM/BPaL) based on bedaquiline, pretomanid and linezolid, with moxifloxacin added when needed, are now preferentially recommended as 6–9-month regimens in WHO and Korean guidelines. During treatment, liver enzymes (hepatotoxicity related to isoniazid, rifampin, pyrazinamide and bedaquiline), visual fields and visual acuity (ethambutol), QT interval (bedaquiline, moxifloxacin, clofazimine), and hearing and renal function (aminoglycosides) should be monitored regularly, and adherence management through psychosocial support, financial assistance and medication reminders directly affects the treatment success rate.


11. Prognosis

The cure rate of drug-susceptible tuberculosis that is properly diagnosed and treated with a complete standard regimen is known to exceed 95%. However, global treatment outcomes based on WHO 2018 cohort data show treatment success rates of about 85% in new and relapse patients, about 76% in HIV-coinfected patients, and only about 57% in multidrug-resistant tuberculosis patients, demonstrating marked prognostic differences according to the degree of resistance and immune status. Indeed, as of 2024, only about 2 in 5 patients with multidrug-resistant/rifampin-resistant tuberculosis accessed treatment, so even when a diagnosis has been made, access to treatment itself acts as a major factor limiting prognosis.

Based on observational studies from the era before anti-tuberculosis drugs were introduced, the natural course of untreated active tuberculosis is estimated to reach a cumulative mortality of about 70% within about 10 years, with the remainder reported to progress to spontaneous healing through natural fibrosis or to a state of chronic bacillary shedding. Major factors worsening prognosis include delayed diagnosis, extensive cavitary lesions, drug resistance, HIV coinfection and severe immunosuppression, malnutrition, old age, comorbidities such as diabetes and chronic renal failure, treatment nonadherence, and reduced access to healthcare due to socioeconomic vulnerability. Severe disseminated forms such as tuberculous meningitis and miliary tuberculosis have relatively high mortality and incidence of neurological sequelae even when diagnosed and treated promptly.

An area recently emphasized clinically is 'post-TB lung disease' that remains even after completion of treatment: in a considerable number of cured patients, chronic respiratory sequelae such as bronchiectasis, pulmonary fibrosis and decreased lung function (reduced FEV1) persist, which may lead in the long term to reduced quality of life and increased risk of excess mortality. Against this background, the Korean tuberculosis treatment guidelines (5th edition, 2024) newly added management of sequelae through assessment of lung function and imaging after completion of treatment as a guideline item. In addition, relapse can occur at a rate of about 2–5% even in patients who have completed the standard regimen and been declared cured, so for those with extensive lesions or incomplete treatment adherence, follow-up of the clinical course for a certain period after completion of treatment is recommended. Overall, the prognosis of tuberculosis is largely determined by early diagnosis, selection of an appropriate initial regimen based on rapid molecular resistance testing, and adherence management through to completion of treatment.


12. Prevention

Tuberculosis prevention strategy consists of three pillars: vaccination, treatment of latent infection, and transmission control. The BCG vaccine is a live attenuated Mycobacterium bovis vaccine developed in 1921, administered shortly after birth in high- and intermediate-burden tuberculosis countries, including Korea. BCG is well established as effective in preventing severe and disseminated tuberculosis in infants and young children, such as miliary tuberculosis and tuberculous meningitis, but the duration of individual protection tends to be limited to childhood, and it is reported not to consistently prevent adult pulmonary tuberculosis or infection itself. An individual participant data meta-analysis by Martinez et al. (Lancet Global Health, 2022) also confirmed that BCG vaccination in infancy provides a certain level of protection across the lifespan, but that its degree and duration are limited; for this reason, many low-burden countries have adopted policies of selective vaccination of high-risk groups rather than universal vaccination.

The second pillar, management of latent tuberculosis infection, is a key strategy for fundamentally reducing tuberculosis incidence: by screening high-risk groups such as people living with HIV, close contacts and candidates for immunosuppressive therapy, and treating them with short-course regimens such as the 3-month rifapentine + isoniazid regimen, subsequent progression to active tuberculosis can be reduced by 60–90%. For contacts of patients with multidrug-resistant tuberculosis, preventive therapy using levofloxacin or similar agents is considered.

Contact investigation for the third pillar, transmission control, is carried out systematically in stages: evaluation of the index patient, identification of places where transmission may have occurred, prioritization of contacts by risk (starting with close contacts according to the concentric circle concept), diagnostic and public health evaluation, and provision of treatment to those found to be infected. Infection control in healthcare facilities consists of a three-level hierarchy of administrative measures (designation of a tuberculosis control officer, risk assessment, staff education), environmental measures (negative-pressure isolation rooms, HEPA filters, ultraviolet germicidal irradiation), and use of personal protective equipment (respiratory protection such as N95 masks); for patients with suspected or confirmed tuberculosis, airborne precautions are maintained until clinical improvement and 3 consecutive negative sputum smears are confirmed.

The WHO End TB Strategy (2014) aims for a 90% reduction in tuberculosis incidence and a 95% reduction in mortality by 2035 compared with 2015, and sets out three pillars: integrated, patient-centered care and prevention; bold policies and supportive systems; and intensified research and innovation. Alongside this, tuberculosis control programs in Korea operate in a way that improves the transmission environment itself, combined with socioeconomic interventions such as the mandatory notification system under the Tuberculosis Prevention Act, latent tuberculosis screening of workers in specific facilities, and nutritional support.


13. References

  1. World Health Organization. Global Tuberculosis Report 2024. Geneva: WHO; 2024. who.int

  2. Adigun R, Singh R. Tuberculosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 28722945. NBK441916

  3. Price DA, Nguyen M. Latent Tuberculosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. NBK599527

  4. StatPearls Publishing. Tuberculosis Prevention, Control, and Elimination. In: StatPearls [Internet]. Treasure Island (FL); 2024 (updated). PMID: 30020618. NBK513246

  5. Korea Disease Control and Prevention Agency. Tuberculosis treatment guidelines (5th edition). Sejong: Korea Disease Control and Prevention Agency; 2024. kdca.go.kr

  6. Korea Disease Control and Prevention Agency. Annual report on the notified tuberculosis patients in Korea, 2024. Osong: Korea Disease Control and Prevention Agency; 2025. dportal.kdca.go.kr

  7. Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, Schumacher SG, Ochodo EA, Pai M, Steingart KR. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2019;6(6):CD009593. DOI: 10.1002/14651858.CD009593.pub4. PMID: 31173647.

  8. Paton NI, Cousins C, Suresh C, et al. Treatment Strategy for Rifampin-Susceptible Tuberculosis. N Engl J Med. 2023;388(10):873-887. DOI: 10.1056/NEJMoa2212537. PMID: 37314715.

  9. Li X, Yang Y, Zhou F, Zhang Y, Lu H, Jin Q, Gao L. SLC11A1 (NRAMP1) Polymorphisms and Tuberculosis Susceptibility: Updated Systematic Review and Meta-Analysis. PLoS One. 2011;6(1):e15831. DOI: 10.1371/journal.pone.0015831. PMID: 21283567.

  10. Martinez L, Cords O, Liu Q, et al. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. Lancet Glob Health. 2022;10(9):e1307-e1316.